Investor Centre

Improving life with rapid testing

Board and Governance

Chris Hand Chairman of Abingdon Health

Dr Chris Hand

Non-Executive Chairman

Chris co-founded Abingdon Health in 2008 and was Chief Executive Officer from 2008 to 2015. He has been Chairman of the business since 2015. He has over 30 years’ experience in the medical diagnostics industry and has specialised in the development and commercialisation of immunodiagnostics products, particularly rapid tests. Chris co-founded the medical diagnostics company Cozart, leading the company’s AIM IPO in 2004 and successful exit to Concateno plc in October 2007. Chris was a Non-Executive Director of Advanced Computer Software plc between 2013 and 2015 when the company was sold to US Private Equity firm Vista for £750m.

CEO of Abindgon Health: Chris Yates

Chris Yates

CEO

Chris was a co-founder of Abingdon Health in 2008 and initially served as a Non-Executive Director before becoming Chief Executive Officer in July 2015. Chris was previously Chief Financial Officer at Cozart, Nexus Vehicle Rental and Immunodiagnostic Systems. Chris is non-executive director of genedrive plc. Chris spent the early part of his career working in Corporate Finance and is a Fellow of the Institute of Chartered Accountants in England & Wales.

Scott Page, Finance Director at Abingdon Health

Scott Page

Finance Director

Scott joined Abingdon Health as Group Financial Controller in July 2017 and was promoted to Finance Director in January 2020. Scott’s previous roles include as a Financial Accountant and then Accounting Manager and Site Controller at Aptar UK. Scott spent the early part of his career working in the audit industry and is a Fellow of the Association of Certified Chartered Accountants.

A picture of Abingdon Health's Non-Executive Director, Lyn Rees

Lyn Rees

Non-executive Director

Lyn joined Abingdon Health as a Non-executive director in June 2020. Lyn is Chief Executive Officer of AIM-listed Yourgene Health plc, an international molecular diagnostics group. He was previously at British Biocell International where his roles included Managing Director of BBI Healthcare and then Chief Executive Officer of the BBI Group. Lyn is also Non-executive Director of Concepta plc.

Mary Taverner NED and board member at Abingdon Health

Mary Tavener

Non-executive Director

Mary has extensive experience in the healthcare sector, having spent more than 19 years as Chief Financial Officer and Board member of AIM listed Advanced Medical Solutions. At AMS, Mary was responsible for strategy and risk management, finance, operations, regulatory, and legal. During her tenure through to the end of 2018, AMS delivered 15 consecutive years of growth, listed on AIM, and successfully conducted several transformational M&A deals. Mary is a member of the Chartered Institute of Management Accountants (ACMA) and a Fellow of the Association of Corporate Treasurers (FCT). Prior to joining AMS, Mary was the Group Financial Controller of BTP plc. She is a non-executive director of AIM listed Allergy Therapeutics plc and chairs the audit committee.

Corporate Governance

Click here

Audit Committee

Chaired by: Mary Tavener

Other Members: Lyn Rees

The Audit Committee is appointed by the Board from amongst the Non-executive Directors of the Group.

How often does the Committee meet?

The Audit Committee meets at least four times a year at appropriate times in the reporting and audit cycle and otherwise as required.

What are the main responsibilities of the Audit Committee?

The Committee’s responsibilities are set out in its terms of reference. The role of the Committee is to assist the board in fulfilling its oversight responsibilities by reviewing and monitoring:

  • the integrity of the financial and narrative statements and other financial information provided to shareholders;
  • the Company’s system of internal controls and risk management;
  • the internal and external audit process and auditors;
  • the processes for compliance with laws, regulations and ethical codes of practice;
  • the Company’s attitude to and appetite for risk and its future risk strategy; and
  • how risk is reported internally and externally.

The Audit Committee is required to report its findings to the Board, identifying any matters in respect of which it considers that action or improvement is needed and make recommendations as to the steps to be taken.

Who is the Group’s Auditor?

BDO LLP is the Group’s current Auditor, having originally been appointed in 2016.  There are no contractual obligations restricting the Company’s choice of external auditor.

What is the policy on the Auditor providing non-audit services?

In order to seek to preserve auditor objectivity and independence, the Company monitors the provision of non-audit services by the Auditor.  Such services are subject to the approval of the Group Finance Director and the Audit Committee.  The ratio of audit fees to non-audit fees charged by the external auditor in any one year as a proportion of the annual external audit fee is kept under regular review to ensure that neither their independence nor their objectivity is put at risk.

Remuneration Committee

Chaired by: Lyn Rees

Other Members: Mary Tavener

The Remuneration Committee is appointed by the Board from amongst the Non-executive Directors of the Group.

How often does the Committee meet?

The Remuneration Committee meets at least twice a year at appropriate times and otherwise as required.

What are the main responsibilities of the Remuneration Committee?

The Committee’s responsibilities are set out in its terms of reference. The role of the Committee is to assist the board in fulfilling its oversight responsibilities by reviewing and monitoring remuneration strategy including:

  • determine and agree with the board the framework or broad policy for the remuneration of the Company’s chairperson and the executive directors including pension rights and compensation payments;
  • the Committee shall recommend and monitor the level and structure of remuneration for senior management;
  • the Committee shall review the ongoing appropriateness and relevance of the remuneration policy; and
  • the Committee shall approve the design of, and determine targets for, any performance related pay schemes operated by the Group and approve the total annual payments made under such schemes.

The Remuneration Committee is required to report its findings to the Board, identifying any matters in respect of which it considers that action or improvement is needed and make recommendations as to the steps to be taken.

What is the objective of the Remuneration Committee?

The objective of the Remuneration Committee is to ensure that remuneration is appropriate to attract, retain and motivate the executive management of the company without paying more than necessary. The remuneration policy will bear in mind the Company’s appetite for risk and be aligned to the Company’s long term strategic goals. A significant proportion of remuneration should be structured so as to link rewards to corporate and individual performance and be designed to promote the long term success of the Company.

Nomination Committee – The Board has concluded that the Group does not currently require a Nominations Committee but will review this assessment on a regular basis including discussing the matter with its Nominated Advisor.

For all investor relations enquiries, please contact Consilium Strategic Communications at: [email protected].